Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00293540 · ClinicalTrials.gov registry record · Phase 3
Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer
A Phase 3 study of Breast Cancer, sponsored by International Breast Cancer Research Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 249
- Enrollment target
- 20
- Study locations
NCT00293540: Completed Phase 3 study of Breast Cancer, sponsored by International Breast Cancer Research Foundation.
NCT00293540 is a Phase 3 study of Breast Cancer that has completed, run by International Breast Cancer Research Foundation. The registered enrollment target is 249 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00293540, a Phase 3 study of Breast Cancer, has completed, sponsored by International Breast Cancer Research Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 249 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will determine if hormone receptor positive premenopausal metastatic breast cancer patients who undergo removal of the ovaries in mid-luteal versus mid-follicular phase have a longer survival.
Conditions Studied
Interventions
- DRUG Tamoxifen
- PROCEDURE oophorectomy
Study Locations (20)
Other
- Dhaka Medical College Hospital - Dhaka
- Beijing Hospital - Beijing
- Cancer Institute - Beijing
- Choa Yang Capital Institute - Beijing
- National Railroad - Beijing
- Peoples Hospital - Beijing
- Qilu Hospital - Jinan
- Fudan University - Shanghai
- Nizam's Institute - Hyderabaad
- Dr. Ciptomanounkusumo General Hospital - Jakarta
- UN. Mayala - Kuala Lumpur
- National Institute of Oncology - Rabat
- University College Hospital - Ibadan
- East Avenue Medical Center - Manila
- Jose Reyes - Manila
- Philippines General Hospital - Manila
- Rizal - Manila
- Vicente Sotto Hospital - Manila
Ohio
- Ohio State University - Columbus
Hebei
- 4th Hospital of Hebei Medical University - Shijiazhuang
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2006-02 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00293540
The ClinicalTrials.gov registry entry for NCT00293540 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 249 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The listed sponsor is International Breast Cancer Research Foundation, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Tamoxifen is the first listed.
NCT00293540 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, Ohio, Hebei.
Frequently Asked Questions
What is clinical trial NCT00293540 about?
NCT00293540 is a clinical study titled "Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer". This study will determine if hormone receptor positive premenopausal metastatic breast cancer patients who undergo removal of the ovaries in mid-luteal versus mid-follicular phase have a longer survival.
What is the current status of trial NCT00293540?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 249 participants. The study started on 2006-02. Estimated completion is 2015-03.
What conditions does trial NCT00293540 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00293540?
The interventions under investigation include: Tamoxifen (DRUG), oophorectomy (PROCEDURE).
Who is sponsoring clinical trial NCT00293540?
This trial is sponsored by International Breast Cancer Research Foundation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00293540 being conducted?
This trial has 20 study locations across Ohio, Hebei. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.